Glycosphingolipids as Therapeutic Targets and Biomarkers of Lupus Nephritis
Abstract
The oseltamivir phosphate (OP) treatment of the MRL/lpr lupus prone strain has been completed for half of the mice and most samples analyzed, including proteinuria, renal pathology, circulating activated T cell numbers, kidney glycosphingolipid levels, and spleen weight and length. Treatment of the remaining half of the MRL/lpr mice was just completed and sample we are investigating the role of NEU1 in the function of renal mesangial cells using cells isolated from the Neu1+/+ and Neu1+/- mice and have demonstrated that NEU mediates cytokine analysis will begin immediately. The B6.SLE1/2/3 genetic study (Neu1+/+ vs Neu1+/- mice) is underway and nearing completion. For the exosome biomarker study, exosomes have been isolated from most of the urine samples and proteomic and lipid discovery analyses run on a subset of samples. Proteomics analysis of this subset identified several proteins previously reported/validated as urine biomarkers of lupus nephritis. Additionally, several proteins were detected predominantly in treatment responders compared to non-responders or predominantly in non-responders compared to responders, which may be useful as biomarkers of response to therapy. These results are being confirmed in the remaining samples. In addition, release in part through a TLR4-MAPK p38 pathway in cells stimulated with lupus serum.
Document Details
- Document Type
- Technical Report
- Publication Date
- Oct 01, 2018
- Accession Number
- AD1093840
Entities
People
- Bethany Wolf
- James Oates
- Jessalyn Rodgers
- Kamala Sundararaj
- Michael G. Janech
- Richard Drake
- Tamara K Nowling
Organizations
- Medical University of South Carolina